中银国际发表研究报告指,三生制药(01530.HK) 去年业绩逊预期,收入按年升94.3%至177亿元人民币,主要受惠于辉瑞(PFE.US) 授权协议所贡献的94亿元人民币授权收入,部分被药物销售疲软所抵销。剔除授权收入后,基本利润因毛利率下降和营运费用增加而下滑。另一方面,被辉瑞定位为下一代免疫肿瘤基石产品的SSGJ-707,鉴于辉瑞已启动和计划于2026年展开相关临床试验,预期公司将可自辉瑞...
Source Link中银国际发表研究报告指,三生制药(01530.HK) 去年业绩逊预期,收入按年升94.3%至177亿元人民币,主要受惠于辉瑞(PFE.US) 授权协议所贡献的94亿元人民币授权收入,部分被药物销售疲软所抵销。剔除授权收入后,基本利润因毛利率下降和营运费用增加而下滑。另一方面,被辉瑞定位为下一代免疫肿瘤基石产品的SSGJ-707,鉴于辉瑞已启动和计划于2026年展开相关临床试验,预期公司将可自辉瑞...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.